Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More French drug price cuts in store as 'stability programme' gets green light

This article was originally published in SRA

Executive Summary

The French pharmaceutical industry is again under the hammer. Parliament has passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period – some €3.5bn of which will affect medicines, and probably medical devices – in the form of selected price cuts, together with moves to increase the market share of generics.

You may also be interested in...



And The UK's First 'Innovation Passport' Goes To... Merck's Rare Disease Drug Belzutifan

The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.

Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up

A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility. 

COVID-19 Vaccine Contracts Rarely Disclose Price & Delivery Details

At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel